Buffered Upper GI Absorption Promoter
The present invention relates to compositions of an active pharmaceutical compound or nutritional ingredient with one or more buffering agents between a pH of 1.0 and 6.0, preferably 2.0 and 4.0. The buffering agents are constituted to maintain or reduce the pH of the duodenal fluid in the proximal, mid and distal duodenum. The present invention further relates to methods of improving the absorption of an iron compound or an active pharmaceutical compound within the small intestine. The present compositions and methods improve absorption or bioavailability of the administered compositions.
1 . A pharmaceutical composition for oral administration to a mammal comprising:
a first nutritional ingredient selected from the group consisting of Sumalate®, Ferrochel®, and DimaCal®; and
a first buffering agent, different from the first nutritional ingredient, with an efficacy in a pH range of 2.0-4.0 selected from the group consisting of Sumalate®, Ferrochel®, ferrous fumarate, ferrous sulfate, DimaCal®, succinic acid, malic acid, glycine and aspartic acid and combinations thereof.
2 . The pharmaceutical composition of claim 1 , wherein the composition comprises between 100 and 600 milligrams of Ferrochel® if this is the first nutritional ingredient, between 100 and 600 milligrams of Sumalate® if this is the first nutritional ingredient, or between 100 and 600 milligrams of DimaCal® if this is the first nutritional ingredient.
3 . The pharmaceutical composition of claim 1 , further comprising a second buffering agent different from the first nutritional ingredient and the first buffering agent, the combination of the first and second buffering agents having an efficacy in a pH range of 2.0-4.0.
4 . The pharmaceutical composition of claim 1 , further comprising a pharmacological agent different from the first nutritional ingredient and the first buffering agent.
5 . The pharmaceutical composition of claim 4 , wherein the pharmacological agent is a second nutritional ingredient.
6 . The pharmaceutical composition of claim 5 , wherein the second nutritional ingredient is a mineral or mineral complex.
7 . The pharmaceutical composition of claim 6 , wherein the second nutritional ingredient is an iron compound consisting of iron as a salt, chelate, complex or mixtures thereof.
8 . The pharmaceutical composition of claim 6 , wherein the second nutritional ingredient is a calcium compound consisting of calcium as a salt, chelate, complex or mixtures thereof.
9 . The pharmaceutical composition of claim 4 , wherein the pharmacological agent is a drug selected from the group comprising an acid/alkaline-labile agent, a pH-dependent agent, or an agent that is a weak acid or a weak base, and mixtures thereof.
10 . The pharmaceutical composition for oral administration to a mammal comprising:
between 200-350 milligrams Ferrochel®;
between 300-400 milligrams malic acid; and
a drug selected from the group comprising an acid/alkaline-labile agent, a pH-dependent agent, or an agent that is a weak acid or a weak base, and mixtures thereof,
the pharmaceutical composition increasing bioavailability of the orally administered combination from 5.0% to 50.0%.
11 . A method of improving absorption within the small intestine of a mammal comprising:
combining a first nutritional ingredient selected from the group consisting of Sumalate®, Ferrochel®, and DimaCal® with a first buffering agent selected from the group consisting of Sumalate®, Ferrochel®, ferrous fumarate, ferrous sulfate, DimaCal®, succinic acid, malic acid, glycine and aspartic acid and combinations thereof, wherein the first buffering agent is different from the first nutritional agent and has an efficacy in a pH range of 2.0-4.0; and
orally administering the combination to a mammal to prolong the length of the small intestine where the duodenal fluid is maintained between a pH of 2.0 and 4.0 from 0.1 to 20 cm.
12 . The method of claim 11 , wherein the combination comprises between 100 and 600 milligrams of Ferrochel® if this is the first nutritional ingredient, between 100 and 600 milligrams of Sumalate® if this is the first nutritional ingredient, or between 100 and 600 milligrams of DimaCal® if this is the first nutritional ingredient.
13 . The method of claim 11 , further comprising combining the first nutritional ingredient and the first buffering agent with a second buffering agent different from the first nutritional ingredient and the first buffering agent, the combination of the first and second buffering agents having an efficacy in a pH range of 2.0-4.0.
14 . The method of claim 11 , further comprising combining the first nutritional ingredient and the first buffering agent with a pharmacological agent different from the first nutritional ingredient and the first buffering agent.
15 . The method of claim 14 , wherein pharmacological agent is a drug selected from the group comprising an acid/alkaline-labile agent, a pH-dependent agent, or an agent that is a weak acid or a weak base, and mixtures thereof.
16 . The method of claim 15 , wherein the length of the small intestine where the duodenal fluid is maintained between a pH of 2.0 and 4.0, increases bioavailability of the orally administered combination from 5.0% to 50.0%.